Literature DB >> 10589594

Parenchyma-preserving hepatectomy in the surgical treatment of hilar cholangiocarcinoma.

M Miyazaki1, H Ito, K Nakagawa, S Ambiru, H Shimizu, T Okaya, K Shinmura, N Nakajima.   

Abstract

BACKGROUND: Although extended hepatic resection has been shown to improve prognosis by increasing the surgical curability rate in hilar cholangiocarcinoma, high surgical morbidity and mortality rates have been reported in patients with obstructive jaundice. Postoperative liver failure after hepatic resection in patients with obstructive jaundice has been shown to depend on the volume of the resected hepatic mass. The aim of this study was to evaluate the results of parenchyma-preserving hepatectomy in a surgical treatment for hilar cholangiocarcinoma. STUDY
DESIGN: Ninety-three resected patients with hilar cholangiocarcinoma were included in this retrospective study. The resected patients were stratified into three groups: the extended hepatectomy (EXH) group (n = 66), the parenchyma-preserving hepatectomy (PPH) group (n = 14), and the local resection (LR) group (n = 13). The EXH group had undergone hepatectomy more extensive than hemihepatectomy, the PPH group had undergone hepatectomy less extensive than hemihepatectomy, and the LR group had undergone extrahepatic bile duct resection without hepatic resection. Surgical curability, defined by histologically confirmed negative surgical margins, surgical morbidity and mortality, and survival rates were compared among the three groups. The clinicopathologic factors were studied for prognostic value by univariate and multivariate analyses.
RESULTS: Surgical curability of the PPH and EXH groups was better than that of the LR group. Fifty-four percent of patients in the LR group showed positive surgical margins at the hepatic stump of the bile duct, compared with 7% in the PPH group and 20% in the EXH groups (p < 0.01 for each comparison). Surgical morbidity was higher in the EXH group (48%) than in the LR group (8%) and the PPH group (14%) (p < 0.01 and p < 0.05, respectively). Postoperative hyperbilirubinemia occurred more frequently in the EXH group (29%) than in the LR and PPH groups (0% and 0%, respectively, p < 0.05 for each comparison). Survival rates after resection were significantly higher in patients who underwent hepatectomy, including PPH and EXH, than in patients who underwent LR, 29% versus 8% at 5 years, respectively (p < 0.05). But no significant difference in survival was found between the PPH and EXH groups. Univariate and multivariate analyses showed that significant prognostic factors for survival were resected margin, lymph nodal status, and vascular resection.
CONCLUSIONS: In conclusion, PPH could obtain a curative resection and improve the outcomes for patients with hilar cholangiocarcinoma that is localized at the hepatic duct confluence who do not require vascular resection. PPH might bring about a beneficial effect in highly selected patients according to extent of cancer and high-risk patients with liver dysfunction.

Entities:  

Mesh:

Year:  1999        PMID: 10589594     DOI: 10.1016/s1072-7515(99)00219-7

Source DB:  PubMed          Journal:  J Am Coll Surg        ISSN: 1072-7515            Impact factor:   6.113


  38 in total

1.  [Hilar cholangiocarcinoma -- results of en bloc resection of tumor and liver].

Authors:  G Otto; J Thies; M Hoppe-Lotichius; F Bittinger; M B Pitton; A Hadian
Journal:  Chirurg       Date:  2004-01       Impact factor: 0.955

2.  Bile duct surgery in the treatment of hepatobiliary and gallbladder malignancies: effects of hepatic and vascular resection on outcomes.

Authors:  Perry Shen; Nora Fino; Edward A Levine; Pamela Eversole; Clancy Clark
Journal:  HPB (Oxford)       Date:  2015-09-16       Impact factor: 3.647

3.  Effect of obstructive jaundice on hepatic hemodynamics: use of Sonazoid-enhanced ultrasonography in a prospective study of the blood flow balance between the hepatic portal vein and hepatic artery.

Authors:  Noritaka Wakui; Yuki Takeda; Shuta Nishinakagawa; Nobuo Ueki; Takafumi Otsuka; Nobuyuki Oba; Hiroshi Hashimoto; Naohisa Kamiyama; Yasukiyo Sumino; Tatsuya Kojima
Journal:  J Med Ultrason (2001)       Date:  2015-04-08       Impact factor: 1.314

4.  Isolated caudate lobectomy with pancreatoduodenectomy for a bile duct cancer.

Authors:  Tsuyoshi Sano; Yasuhiro Shimizu; Yoshiki Senda; Koji Komori; Seiji Ito; Tetsuya Abe; Taira Kinoshita; Yuji Nimura
Journal:  Langenbecks Arch Surg       Date:  2013-09-13       Impact factor: 3.445

5.  One hundred two consecutive hepatobiliary resections for perihilar cholangiocarcinoma with zero mortality.

Authors:  Tsuyoshi Sano; Kazuaki Shimada; Yoshihiro Sakamoto; Junji Yamamoto; Susumu Yamasaki; Tomoo Kosuge
Journal:  Ann Surg       Date:  2006-08       Impact factor: 12.969

6.  Operative considerations in resection of hilar cholangiocarcinoma.

Authors:  Alexander A Parikh; Eddie K Abdalla; Jean-Nicolas Vauthey
Journal:  HPB (Oxford)       Date:  2005       Impact factor: 3.647

7.  Radical surgery for right-sided klatskin tumor.

Authors:  P Neuhaus; A Thelen
Journal:  HPB (Oxford)       Date:  2008       Impact factor: 3.647

8.  Surgical treatment of hilar bile duct carcinoma: experience with 25 consecutive hepatectomies.

Authors:  Yoshifumi Kawarada; Bidhan C Das; Tatsushi Naganuma; Masami Tabata; Hiroki Taoka
Journal:  J Gastrointest Surg       Date:  2002 Jul-Aug       Impact factor: 3.452

9.  Long-term outcome of extended hemihepatectomy for hilar bile duct cancer with no mortality and high survival rate.

Authors:  Yasuji Seyama; Keiichi Kubota; Keiji Sano; Tamaki Noie; Tadatoshi Takayama; Tomoo Kosuge; Masatoshi Makuuchi
Journal:  Ann Surg       Date:  2003-07       Impact factor: 12.969

10.  Initial presentation and management of hilar and peripheral cholangiocarcinoma: is a node-positive status or potential margin-positive result a contraindication to resection?

Authors:  Kevin Tri Nguyen; Jennifer Steel; Tsafrir Vanounou; Allan Tsung; J Wallis Marsh; David A Geller; T Clark Gamblin
Journal:  Ann Surg Oncol       Date:  2009-09-23       Impact factor: 5.344

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.